FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3181280317> ?p ?o ?g. }

• W3181280317 abstract "Protein arginine methyltransferase 5 (PRMT5) overexpression in hematological and solid tumors promotes symmetrical di-methyl arginine (SDMA) on cellular proteins involved in important cancer functions including cell cycle regulation, mRNA splicing, cell differentiation, cell signaling, and apoptosis. PRMT5 methyltransferase function has been linked with high rates of tumor cell proliferation and decreased overall survival, and PRMT5 inhibitors are currently being explored as an approach for targeting cancer-specific dependencies due to PRMT5 catalytic function. Here we describe the discovery of potent and selective S-adenosylmethionine (SAM) competitive PRMT5 inhibitors, including the clinical candidate PF-06939999. Acquired resistance mechanisms were explored through the development of drug resistant cell lines. Our data highlight compound-specific resistance mutations in the PRMT5 enzyme that demonstrate structural constraints in the co-factor binding site that prevent emergence of complete resistance to SAM site inhibitors. PRMT5 inhibition by PF-06939999 treatment reduced proliferation of NSCLC cancer cells, with dose-dependent decreases in SDMA levels and changes in alternative splicing of numerous pre-mRNAs. Drug sensitivity associates with cancer pathways including MYC, cell cycle and splicing. Translation of efficacy in mouse tumor xenograft models with splicing mutations provides rationale for therapeutic use of PF-06939999 for treatment of splicing dysregulated NSCLC.Citation Format: Kristen Jensen-Pergakes, John Tatlock, Karen Maegley, Indrawan McAlpine, Michele McTigue, Tao Xie, Christopher Dillon, Yuli Wang, Shinji Yamazaki, Noah Spiegel, Manli Shi, Amy Nemeth, Natalie Miller, Eleanore Hendrickson, Hieu Lam, John Sherrill, Wei Liu, Ya-Li Deng, Chi-Yeh Chung, Elizabeth A. McMillan, Prakash Palde, Alexei Brooun, John Braganza, Susan E. Kephart, Robert Kumpf, Ryan Patman, Eugene Rui, Stephanie Scales, Michelle Tran-Dube, Fen Wang, Martin Wythes, Thomas Paul. SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1160." @default.
• W3181280317 created "2021-07-19" @default.
• W3181280317 creator A5000972962 @default.
• W3181280317 creator A5003348856 @default.
• W3181280317 creator A5006034799 @default.
• W3181280317 creator A5006518535 @default.
• W3181280317 creator A5011477337 @default.
• W3181280317 creator A5023836589 @default.
• W3181280317 creator A5029169442 @default.
• W3181280317 creator A5031081898 @default.
• W3181280317 creator A5034079121 @default.
• W3181280317 creator A5039754491 @default.
• W3181280317 creator A5039784780 @default.
• W3181280317 creator A5045280982 @default.
• W3181280317 creator A5045935502 @default.
• W3181280317 creator A5047085319 @default.
• W3181280317 creator A5055929834 @default.
• W3181280317 creator A5056150876 @default.
• W3181280317 creator A5060126949 @default.
• W3181280317 creator A5063500857 @default.
• W3181280317 creator A5064787088 @default.
• W3181280317 creator A5065104999 @default.
• W3181280317 creator A5069163138 @default.
• W3181280317 creator A5069516330 @default.
• W3181280317 creator A5071409456 @default.
• W3181280317 creator A5074538933 @default.
• W3181280317 creator A5074892381 @default.
• W3181280317 creator A5075130252 @default.
• W3181280317 creator A5079660804 @default.
• W3181280317 creator A5079880890 @default.
• W3181280317 creator A5083705936 @default.
• W3181280317 creator A5084016503 @default.
• W3181280317 creator A5089644945 @default.
• W3181280317 creator A5091610253 @default.
• W3181280317 date "2021-07-01" @default.
• W3181280317 modified "2023-10-16" @default.
• W3181280317 title "Abstract 1160: SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance" @default.
• W3181280317 doi "https://doi.org/10.1158/1538-7445.am2021-1160" @default.
• W3181280317 hasPublicationYear "2021" @default.
• W3181280317 type Work @default.
• W3181280317 sameAs 3181280317 @default.
• W3181280317 citedByCount "0" @default.
• W3181280317 crossrefType "proceedings-article" @default.
• W3181280317 hasAuthorship W3181280317A5000972962 @default.
• W3181280317 hasAuthorship W3181280317A5003348856 @default.
• W3181280317 hasAuthorship W3181280317A5006034799 @default.
• W3181280317 hasAuthorship W3181280317A5006518535 @default.
• W3181280317 hasAuthorship W3181280317A5011477337 @default.
• W3181280317 hasAuthorship W3181280317A5023836589 @default.
• W3181280317 hasAuthorship W3181280317A5029169442 @default.
• W3181280317 hasAuthorship W3181280317A5031081898 @default.
• W3181280317 hasAuthorship W3181280317A5034079121 @default.
• W3181280317 hasAuthorship W3181280317A5039754491 @default.
• W3181280317 hasAuthorship W3181280317A5039784780 @default.
• W3181280317 hasAuthorship W3181280317A5045280982 @default.
• W3181280317 hasAuthorship W3181280317A5045935502 @default.
• W3181280317 hasAuthorship W3181280317A5047085319 @default.
• W3181280317 hasAuthorship W3181280317A5055929834 @default.
• W3181280317 hasAuthorship W3181280317A5056150876 @default.
• W3181280317 hasAuthorship W3181280317A5060126949 @default.
• W3181280317 hasAuthorship W3181280317A5063500857 @default.
• W3181280317 hasAuthorship W3181280317A5064787088 @default.
• W3181280317 hasAuthorship W3181280317A5065104999 @default.
• W3181280317 hasAuthorship W3181280317A5069163138 @default.
• W3181280317 hasAuthorship W3181280317A5069516330 @default.
• W3181280317 hasAuthorship W3181280317A5071409456 @default.
• W3181280317 hasAuthorship W3181280317A5074538933 @default.
• W3181280317 hasAuthorship W3181280317A5074892381 @default.
• W3181280317 hasAuthorship W3181280317A5075130252 @default.
• W3181280317 hasAuthorship W3181280317A5079660804 @default.
• W3181280317 hasAuthorship W3181280317A5079880890 @default.
• W3181280317 hasAuthorship W3181280317A5083705936 @default.
• W3181280317 hasAuthorship W3181280317A5084016503 @default.
• W3181280317 hasAuthorship W3181280317A5089644945 @default.
• W3181280317 hasAuthorship W3181280317A5091610253 @default.
• W3181280317 hasConcept C104317684 @default.
• W3181280317 hasConcept C105580179 @default.
• W3181280317 hasConcept C111819275 @default.
• W3181280317 hasConcept C121608353 @default.
• W3181280317 hasConcept C194583182 @default.
• W3181280317 hasConcept C29537977 @default.
• W3181280317 hasConcept C33288867 @default.
• W3181280317 hasConcept C40000846 @default.
• W3181280317 hasConcept C502942594 @default.
• W3181280317 hasConcept C54355233 @default.
• W3181280317 hasConcept C54458228 @default.
• W3181280317 hasConcept C55493867 @default.
• W3181280317 hasConcept C62112901 @default.
• W3181280317 hasConcept C67705224 @default.
• W3181280317 hasConcept C71924100 @default.
• W3181280317 hasConcept C86803240 @default.
• W3181280317 hasConcept C91965660 @default.
• W3181280317 hasConceptScore W3181280317C104317684 @default.
• W3181280317 hasConceptScore W3181280317C105580179 @default.
• W3181280317 hasConceptScore W3181280317C111819275 @default.
• W3181280317 hasConceptScore W3181280317C121608353 @default.
• W3181280317 hasConceptScore W3181280317C194583182 @default.
• W3181280317 hasConceptScore W3181280317C29537977 @default.
• W3181280317 hasConceptScore W3181280317C33288867 @default.
• W3181280317 hasConceptScore W3181280317C40000846 @default.

• next